Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (GB:0HX7)
LSE:0HX7
0HX7 Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.78 - $2.43
Previous CloseN/A
Volume2.90K
Average Volume (3M)11.91K
Market Cap
$63.09M
Enterprise Value-$53.05M
Total Cash (Recent Filing)$7.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
May 20, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding82,685,750
10 Day Avg. Volume4,415
30 Day Avg. Volume11,912
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)88.36
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.48
Forecast
1Y Price Target
$8.00Price Target Upside952.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
---
Adicet Bio News
---
Bulls Say, Bears Say
Bulls Say
FDA DesignationADI-001 has been granted FDA Fast Track Designation for the potential treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement, adult patients with systemic sclerosis (SSC), and patients with relapsed or refractory class III or class IV lupus nephritis (LN).
Financial StabilityAdicet highlights a solid cash position of $176.3MM, indicating financial stability.
Bears Say
Revenue PerformanceFor 4Q24, Adicet reported no revenues, aligning with expectations but still a negative indicator.
---
Options Prices
Currently, No data available
---
Ownership Overview
15.69% Insiders
6.31% Mutual Funds
47.42% Other Institutional Investors
26.07% Public Companies and Individual Investors
0HX7 FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest share price was $0.78 and its highest was $2.43 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $63.09M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 20, 2025 which is in 69 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 06, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.037.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio does not currently pay dividends.
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -0.33.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 82,685,750 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -7.36%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in GB:0HX7
---
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (952.63% Upside)
$8.00 (952.63% Upside)
Blogger Sentiment
Bullish
GB:0HX7 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.60%
12-Months-Change
Fundamentals
Return on Equity
-65.65%
Trailing 12-Months
Asset Growth
6.23%
Trailing 12-Months
Company Description
Adicet Bio
resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.
---
0HX7 Stock 12 Month Forecast
Average Price Target
$8.00
▲(952.63% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering 0HX7
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-13.63%
reiterated a buy rating 7 days ago
Copying John Newman's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -13.63% per trade.
---